08/27/2025 8:45 PM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/22/2025 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Scott Kathleen D. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/22/2025 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Lowenthal Richard E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/21/2025 4:36 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Tanimoto Sarina (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
08/21/2025 3:18 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Scott Kathleen D. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/21/2025 10:20 AM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Lowenthal Richard E (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/19/2025 9:22 AM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Tanimoto Sarina (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2025 6:02 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/13/2025 6:03 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
08/01/2025 5:06 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Flynn James E (Filed by)
| Form SCHEDULE 13D/A | |
07/22/2025 6:38 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Flynn James E (Filed by)
| Form SCHEDULE 13D/A | |
Get the Latest News and Ratings for SPRY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
07/02/2025 7:24 AM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Flynn James E (Filed by)
| Form SCHEDULE 13D/A | |
07/01/2025 3:42 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting) Deerfield Mgmt III, L.P. (Reporting) Deerfield Mgmt IV, L.P. (Reporting) Deerfield Private Design Fund III, L.P. (Reporting) Deerfield Private Design Fund IV, L.P. (Reporting) Flynn James E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/27/2025 4:21 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Kolchinsky Peter (Reporting) RA Capital Healthcare Fund LP (Reporting) RA CAPITAL MANAGEMENT, L.P. (Reporting) RA Capital Nexus Fund II, L.P. (Reporting) Shah Rajeev M. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/27/2025 3:43 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Dadoo Rajeev (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/27/2025 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Shawver Laura (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/27/2025 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) SCHNEIDER PHILLIP M (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/27/2025 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) SAUNDERS BRENT L (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/27/2025 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Thompson Peter A. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/27/2025 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Islam Saqib (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/27/2025 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Kelly Michael (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/27/2025 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Shah Pratik (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/26/2025 3:15 PM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/20/2025 5:38 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Karas Eric (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2025 3:51 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Karas Eric (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2025 4:24 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Scott Kathleen D. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2025 3:48 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) SAUNDERS BRENT L (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2025 3:50 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Fitzpatrick Alexander A (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/14/2025 6:01 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/14/2025 6:03 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/02/2025 7:05 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/08/2025 3:45 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Shawver Laura (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/07/2025 1:26 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Shawver Laura (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/24/2025 6:57 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Flynn James E (Filed by)
| Form SCHEDULE 13D/A | |
03/21/2025 5:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Karas Eric (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/20/2025 3:03 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Karas Eric (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/20/2025 3:05 PM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/20/2025 6:02 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/20/2025 6:04 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
03/07/2025 4:12 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Shawver Laura (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/05/2025 4:18 PM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
Washington prepares for war (Ad) While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII.
According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most. Click here now to watch the urgent wartime exposé |
03/05/2025 4:19 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Shawver Laura (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/04/2025 3:35 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Shawver Laura (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/03/2025 11:06 AM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Shawver Laura (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/31/2025 4:21 PM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form S-3ASR | |
01/13/2025 7:08 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/07/2025 5:24 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Shawver Laura (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/06/2025 3:36 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Shawver Laura (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/19/2024 3:20 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Lowenthal Richard E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/19/2024 3:20 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Tanimoto Sarina (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/13/2024 6:52 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Dorsey Brian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/13/2024 6:53 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Chakma Justin (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/13/2024 4:24 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Chakma Justin (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/12/2024 4:41 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Chakma Justin (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/12/2024 4:02 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Chakma Justin (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/11/2024 5:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Lowenthal Richard E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/11/2024 5:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Tanimoto Sarina (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/11/2024 4:31 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Dorsey Brian (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024 3:48 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Chakma Justin (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/10/2024 10:15 AM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Lowenthal Richard E (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/09/2024 4:43 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Tanimoto Sarina (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/09/2024 4:25 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Lowenthal Richard E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/09/2024 11:38 AM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Shawver Laura (Reporting)
| Form 144/A | |
12/06/2024 6:15 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Chakma Justin (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/06/2024 4:30 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Chakma Justin (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/05/2024 4:06 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Chakma Justin (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/03/2024 4:25 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Chakma Justin (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024 6:01 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Chakma Justin (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024 5:22 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Shawver Laura (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/02/2024 3:42 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Karas Eric (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/27/2024 3:11 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Chakma Justin (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/21/2024 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Tanimoto Sarina (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/21/2024 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Lowenthal Richard E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/15/2024 2:21 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Chakma Justin (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
11/13/2024 7:16 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting) Deerfield Mgmt III, L.P. (Reporting) Deerfield Mgmt IV, L.P. (Reporting) Deerfield Private Design Fund III, L.P. (Reporting) Deerfield Private Design Fund IV, L.P. (Reporting) Flynn James E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
11/13/2024 6:02 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/13/2024 6:00 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/17/2024 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Lowenthal Richard E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/17/2024 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Tanimoto Sarina (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/17/2024 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Scott Kathleen D. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/16/2024 3:01 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Scott Kathleen D. (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024 10:28 AM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Tanimoto Sarina (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024 6:02 AM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/10/2024 3:27 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Lowenthal Richard E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/10/2024 3:28 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Tanimoto Sarina (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/23/2024 3:15 PM | ARS Pharmaceuticals, Inc. (Filer) ARS Pharmaceuticals (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/19/2024 3:26 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Lowenthal Richard E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/19/2024 3:29 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Tanimoto Sarina (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/19/2024 3:30 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Karas Eric (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/18/2024 3:06 PM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Karas Eric (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/12/2024 3:24 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Lowenthal Richard E (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
Washington prepares for war (Ad) While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII.
According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most. Click here now to watch the urgent wartime exposé |
09/12/2024 3:25 PM | ARS Pharmaceuticals, Inc. (Issuer) ARS Pharmaceuticals (Issuer) Tanimoto Sarina (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/10/2024 9:31 AM | ARS Pharmaceuticals, Inc. (Subject) ARS Pharmaceuticals (Subject) Lowenthal Richard E (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |